X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (4) 4
medicine & public health (3) 3
safety and security measures (3) 3
aged (2) 2
breast cancer (2) 2
cancer (2) 2
care and treatment (2) 2
drug administration schedule (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
infusions, intravenous (2) 2
male (2) 2
metastasis (2) 2
middle aged (2) 2
nursing (2) 2
nursing management/nursing research (2) 2
oncology, experimental (2) 2
pain medicine (2) 2
rehabilitation medicine (2) 2
research (2) 2
treatment outcome (2) 2
acute lymphocytic-leukemia (1) 1
administration, cutaneous (1) 1
adolescent (1) 1
adult (1) 1
adults (1) 1
age factors (1) 1
animals (1) 1
antibodies - immunology (1) 1
antibodies, bispecific - administration & dosage (1) 1
antibodies, bispecific - adverse effects (1) 1
antibodies, bispecific - therapeutic use (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
article (1) 1
aurora kinases (1) 1
bisphosphonates (1) 1
bone density conservation agents - administration & dosage (1) 1
bone density conservation agents - adverse effects (1) 1
bone metastases (1) 1
bone neoplasms - drug therapy (1) 1
bone neoplasms - secondary (1) 1
breast neoplasms (1) 1
cancer therapies (1) 1
cardiac surgery (1) 1
cell biology (1) 1
cell extracts (1) 1
cell-engaging antibody (1) 1
cellbio (1) 1
cellcycle (1) 1
centrosome - metabolism (1) 1
chain antibody construct (1) 1
chemotherapy (1) 1
chromatin (1) 1
chromosomal proteins, non-histone - immunology (1) 1
chromosomal proteins, non-histone - metabolism (1) 1
chromosomes - metabolism (1) 1
clinical trials (1) 1
cytokines (1) 1
denosumab (1) 1
denosumab - administration & dosage (1) 1
denosumab - adverse effects (1) 1
developmental biology (1) 1
diphosphonates - administration & dosage (1) 1
diphosphonates - adverse effects (1) 1
disease-free survival (1) 1
double-blind (1) 1
double-blind method (1) 1
drug resistance, neoplasm (1) 1
efficacy (1) 1
embryonic-cell cycle (1) 1
enzyme activation (1) 1
erratum (1) 1
europe (1) 1
free survival (1) 1
general surgery (1) 1
health care sciences & services (1) 1
hematology, oncology and palliative medicine (1) 1
hematopoietic stem cell transplantation (1) 1
histones - metabolism (1) 1
human immunodeficiency virus--hiv (1) 1
imidazoles - administration & dosage (1) 1
imidazoles - adverse effects (1) 1
immunotherapy (1) 1
importin-beta (1) 1
infectious diseases (1) 1
inotuzumab ozogamicin (1) 1
intention to treat analysis (1) 1
kaplan-meier estimate (1) 1
kinase-activity (1) 1
long-term care (1) 1
macromolecular substances (1) 1
mass-spectrometry (1) 1
medical research (1) 1
microtubules - metabolism (1) 1
mitotic spindle (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 57 - 66
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 1/2016, Volume 24, Issue 1, pp. 447 - 455
Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied. Here, we... 
Pain Medicine | Nursing | Rehabilitation Medicine | Medicine & Public Health | Osteonecrosis of the jaw | Zoledronic acid | Oncology | Breast cancer | Denosumab | Prostate cancer | Bone metastases | Nursing Management/Nursing Research | RISK-FACTORS | EFFICACY | FREE SURVIVAL | PREVENTION | OSTEONECROSIS | BISPHOSPHONATES | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | SKELETAL-RELATED EVENTS | DOUBLE-BLIND | REHABILITATION | Humans | Middle Aged | Bone Neoplasms - secondary | Imidazoles - administration & dosage | Male | Long-Term Care | Administration, Cutaneous | Breast Neoplasms | Denosumab - adverse effects | Prostatic Neoplasms | Denosumab - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Female | Bone Neoplasms - drug therapy | Diphosphonates - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Imidazoles - adverse effects | Treatment Outcome | Diphosphonates - administration & dosage | Zoledronic Acid | Bone Density Conservation Agents - administration & dosage | Aged | Infusions, Intravenous | Care and treatment | Safety and security measures | Oncology, Experimental | Clinical trials | Metastasis | Research | Cancer | Cancer therapies | Original
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 3606 - 3606
Abstract Abstract 3606 Introduction: Rigosertib (ON01910.Na) is a non-ATP competitive multi-kinase inhibitor which differentially arrests tumor cells in G2-M... 
Journal Article
2010, ISBN 9783642016523
Poor prognostic factors in the traditional non-Hodgkin's lymphomas (NHL), such as poor performance status, multifocal disease, and increased age, are also poor... 
Nephrology | Medicine & Public Health | Cardiac Surgery | Oncology | Infectious Diseases | General Surgery | Transplant Surgery
Book Chapter
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.